This study reports a comprehensive environmental scan of the generative AI (GenAI) infrastructure in the national network for clinical and translational science across 36 institutions supported by the Clinical and Translational Science Award (CTSA) Program led by the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH) at the United States. With the rapid advancement of GenAI technologies, including large language models (LLMs), healthcare institutions face unprecedented opportunities and challenges. This research explores the current status of GenAI integration, focusing on stakeholder roles, governance structures, and ethical considerations by administering a survey among leaders of health institutions (i.e., representing academic medical centers and health systems) to assess the institutional readiness and approach towards GenAI adoption. Key findings indicate a diverse range of institutional strategies, with most organizations in the experimental phase of GenAI deployment. The study highlights significant variations in governance models, with a strong preference for centralized decision-making but notable gaps in workforce training and ethical oversight. Moreover, the results underscore the need for a more coordinated approach to GenAI governance, emphasizing collaboration among senior leaders, clinicians, information technology staff, and researchers. Our analysis also reveals concerns regarding GenAI bias, data security, and stakeholder trust, which must be addressed to ensure the ethical and effective implementation of GenAI technologies. This study offers valuable insights into the challenges and opportunities of GenAI integration in healthcare, providing a roadmap for institutions aiming to leverage GenAI for improved quality of care and operational efficiency.

This study proposes the use of Machine Learning models to predict the early onset of sepsis using deidentified clinical data from Montefiore Medical Center in Bronx, NY, USA. A supervised learning approach was adopted, wherein an XGBoost model was trained utilizing 80\% of the train dataset, encompassing 107 features (including the original and derived features). Subsequently, the model was evaluated on the remaining 20\% of the test data. The model was validated on prospective data that was entirely unseen during the training phase. To assess the model's performance at the individual patient level and timeliness of the prediction, a normalized utility score was employed, a widely recognized scoring methodology for sepsis detection, as outlined in the PhysioNet Sepsis Challenge paper. Metrics such as F1 Score, Sensitivity, Specificity, and Flag Rate were also devised. The model achieved a normalized utility score of 0.494 on test data and 0.378 on prospective data at threshold 0.3. The F1 scores were 80.8\% and 67.1\% respectively for the test data and the prospective data for the same threshold, highlighting its potential to be integrated into clinical decision-making processes effectively. These results bear testament to the model's robust predictive capabilities and its potential to substantially impact clinical decision-making processes.